Gynecologic oncology · 2020
Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Crestani Adrien, Benoit Louise, Touboul Cyril, Pasquier Jennifer
Аннотация
The age of cancer as an isolated single-cell concept is now behind us. It is now established that epithelial ovarian cancer, like other cancers, interacts with the healthy bystander cells to influence them and takes advantage of their nutritional, immunological, disseminating and other capacities. This interaction has become a therapeutic target, as shown by the numerous studies on this subject. Intraperitoneal chemo-hyperthermia has been part of the therapeutic armamentarium for some time yet its efficiency in ovarian cancer has only been recently proven in a randomized controlled trial. However, its therapeutic performance is not revolutionary and epithelial ovarian cancer maintains a high mortality. In this review, we studied the impact of HIPEC on the microenvironment and vice versa to determine whether it could be the key to this lukewarm efficacy. We began by exploring the modalities of HIPEC and establishing the reasons that make this treatment topical. Then, we examined its impact on each element of the tumor environment to obtain a global view of the resistance mechanisms at work in HIPEC.
Предметные рубрики MeSH
Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialDrug Resistance, NeoplasmExtracellular MatrixFemaleHumansHyperthermic Intraperitoneal ChemotherapyLymphocytes, Tumor-InfiltratingNeoadjuvant TherapyOvarian NeoplasmsPeritoneumRandomized Controlled Trials as TopicTreatment OutcomeTumor Microenvironment